Living Related Liver Transplantation Across Abo Blood Groups

Tanaka, Akira; Tanaka, Kōichi; Kitai, Toshiyuki; Yanabu, Nobuharu; Tokuka, Atsuo; Sato, Bunpei; Mori, Shigeo; Inomoto, Takuya; Shinohara, Hisashi; Üemoto, Shinji; Tokunaga, Yukihiko; Inomata, Yukihiro; Yamaoka, Yoshio

doi:10.1097/00007890-199409150-00004

Cited by 43 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 The CFSE-labeled cells were cultured in Roswell Park Memorial Institute (RPMI; Nacalai Tesque, Kyoto, Japan) culture medium containing 10% fetal bovine serum (Sanko, Tokyo, Japan), 5 M 2-mercaptoethanol (Katayama, Osaka, Japan), 1% HEPES buffer (GIBCO, Grand Island, NY), and 100 IU/mL penicillin-100 g/mL streptomycin (GIBCO). The following stimuli were added at the start of the culture: 10 g/mL of goat anti-mouse IgM F(abЈ) 2 (Jackson ImmunoResearch Laboratories, West Grove, PA), 1 g/mL recombinant mouse CD40L, and 1 g/mL enhancer (Alexis Cor, Lausen, Switzerland), as well as 0.02 g/mL recombinant mouse IL-4 (R&D Systems, Minneapolis, MN). In the CsA inhibition assay, various doses of CsA (6.25-100 ng/mL; which was kindly provided by Novartis, Basel, Switzerland) were added at the start of the culture.…”

Section: In Vitro B-cell Proliferation Assaymentioning

confidence: 99%

“…Transplantation across ABO blood barriers using living donor organs has been performed with some success. 1,2 Removing anti-A/B antibodies (Abs) by plasma exchange or plasmapheresis, splenectomy, and use of anti-B-cell immunosuppressants in the recipients are widely adopted strategies to avoid Ab-dependent rejection of ABO-incompatible organ grafts. [3][4][5][6][7][8] Despite the use of such therapeutic methods, graft survival in ABO-incompatible organ transplantation is generally inferior compared with that in ABO-compatible transplantation because of the reappearance of anti-A/B Abs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation

Irei

Ohdan

Zhou

et al. 2007

Blood

View full text Add to dashboard Cite

We demonstrated a novel strategy for specific and persistent inhibition of antibody (Ab) production against blood group A or B carbohydrate determinants necessary for successful ABO-incompatible transplantation. Similar to human blood group O or B individuals, mice have naturally occurring Abs against human blood group A carbohydrates in their sera. B cells with receptors for A carbohydrates in mice belonging to the CD5+CD11b+B-1a subset have phenotypic properties similar to those of human B cells. These cells could be temporarily eliminated by injecting synthetic A carbohydrates (GalNAcα1–3, Fucα1–2Gal) conjugated to bovine serum albumin (A-BSA) and anti-BSA Abs. In mice that received the injection of A-BSA/anti-BSA Abs, the serum levels of anti-A IgM were reduced, but immunization with human A erythrocytes resulted in increased serum levels of anti-A Abs. When combined with cyclosporin A (CsA) treatment, which blocks B-1a cell differentiation, and treatment with A-BSA/anti-BSA Abs, the serum levels of anti-A Abs were persistently undetectable in the mice even after the immunization. B cells with receptors for A carbohydrates were markedly reduced in these mice. These results are consistent with the hypotheses that treatment with A-BSA/anti-BSA Abs temporarily depletes B cells responding to A determinants, and CsA treatment prevents the replenishment of these cells.

show abstract

Section: In Vitro B-cell Proliferation Assaymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation

Irei

Ohdan

Zhou

et al. 2007

Blood

View full text Add to dashboard Cite

show abstract

“…12 Patient 4 was less than 2 years old and, with an ABO-incompatible transplant, had no preoperative treatment for ABO incompatibility. 13 This study was approved by the institutional review board, and informed consent was obtained in all the cases.…”

Section: Methodsmentioning

confidence: 99%

Living donor liver transplantation for glycogen storage disease type Ib

et al. 2009

View full text Add to dashboard Cite

Glycogen storage disease type 1b (GSD-1b) is due to an autosomal recessive inborn error of carbohydrate metabolism caused by defects in glucose-6-phosphatase translocase. Patients with GSD-1b have severe hypoglycemia with several clinical manifestations of hepatomegaly, obesity, a doll-like face, and neutropenia. Liver transplantation has been indicated for severe glucose intolerance. This study retrospectively reviewed 4 children with a diagnosis of GSD-1b who underwent living-donor liver transplantation (LDLT). Between November 2005 and June 2008, 96 children underwent LDLT with overall patient and graft survival of 92.3%. Of these, 4 (4.2%) were indicated for GSD-1b. All patients are doing well with an excellent quality of life because of the stabilization of glucose intolerance, decreased hospital admission, and normalized neutrophil count. LDLT appears to be a feasible option and is associated with a better quality of life for patients with GSD-1b. Long-term observation may be necessary to collect sufficient data to confirm the efficacy of this treatment modality.

show abstract

“…Despite these therapeutic manipulations, 1-year graft survival in adult recipients is very significantly reduced at only 20-40%. As re-transplantation can sometimes be carried out successfully with an ABOcompatible graft, patient survival is > 50% [76].…”

Section: Livermentioning

confidence: 99%

ABO-incompatible organ and bone marrow transplantation: current status

Bühler

Cooper

2003

Transplant Int

View full text Add to dashboard Cite

Despite the presence of preformed antibodies against AB oligosaccharide epitopes on the donor vascular endothelium, approximately one-third of ABOincompatible organ allografts are not rejected by a humoral mechanism. With the growing immune-manipulation of the recipient, survival rates can be raised considerably, although they remain significantly inferior to those of ABO-compatible transplantation. Data from the Collaborative Transplant Study indicate a 1-year graft survival rate of approximately 50-60% following cadaveric ABO-incompatible kidney, liver or heart transplantation, compared with 70-80% for an ABO-compatible organ. The results for infants and young children, however, are very much better than those of adults, particularly for Iiver and heart transplantations, and the data suggest that B-cell tolerance can develop in the infant age group. We here review clinical and experimental experience with ABO-incompatible organ and bone marrow allotransplantation and address the mechanisms by which organs or cells survive in the presence of natural anti-carbohydrate antibodies.

show abstract

Living Related Liver Transplantation Across Abo Blood Groups

Cited by 43 publications

References 0 publications

The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation

The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation

Living donor liver transplantation for glycogen storage disease type Ib

ABO-incompatible organ and bone marrow transplantation: current status

Contact Info

Product

Resources

About